Abstract:Objective To explore the long-term effects of risk-based stratification treatment of children with medulloblastoma and elucidate the relationship between risk factors,treatment effects and prognosis.Methods Patients admitted from January 2010 to June 2015 with primary medulloblastoma confirmed by postoperative histopathology were stratified into low-risk or high-risk group.They were stratified on the basis of risk factors,i.e.age,Chang et al's staging system (no metastasis M0,with metastasis M +),complete/near total tumor resection and postoperative residue tumor (tumor residue ≥ 1.5 cm).pathological type (classical medulloblastoma CMB,desmoplastic medulloblastoma DMB,medulloblastoma with extensive nodularity MBEN,large cell medulloblastoma LCMB and anaplatic medulloblastoma AMB).The low-risk group (＞3 years,M0,complete/near total tumor resection,CMB,DMB/MBEN) received postoperative 24～30 Gy craniospinal irradiation followed by a boost of 54～56 Gy to tumor bed in posterior fossa and then 8 cycles of sequential maintenance chemotherapy.In the high-risk group (≤3 years,M +,tumor residue ≥1.5 em,AMB/LCMB),children aged ＞3 years received two-cycles of postoperative induced chemotherapy,followed by 36 Gy craniospinal irradiation and then a boost of 54～56Gy to tumor bed in posterior fossa,followed by 4 cycles of maintenance chemotherapy after irradiation.Children aged ≤3 years received 3 cycles of postoperative induced chemotherapy followed by 4 cycles of maintenance chemotherapy.Results Among 115 children with histologically confirmed primary medulloblastoma,there were 77 boys and 38 girls with a male-to-female ratio of 2.02 ∶ 1.Eight cases were aged under 3 years and 107 cases older than 3.Therefore the median age was 6.75 years (15 months the youngest and 15 years the oldest).The lowrisk group had 60 children (accounting for 52.2％ of total) while 55 children (accounting for 47.8％) were put in high-risk group.The median follow-up period was 25 (6-60) months.The 3-5 year overall survival (OS) was 85.5％ in low-risk group versus 67.7％ in high-risk group.And significant difference existed between two groups (P＜0.05).In addition,3-5 year disease-free survival (DFS) was 76.8％ in low-risk group while 47.3％ in high-risk group.Two groups showed significant intergroup difference (P＜0.05).Among 31 recurrent cases (27.0％),twoof them were aged ≤3 years.The median time of postoperative recurrence was 12 months (4 weeks to 48 months).Among them,2 obtained complete remission and 13 patients showed partial remission.Another 16 patients died,including 1 patient aged ≤ 3 years.One case suffered secondary intracranial high-grade glioma.Conclusions For diagnosis and therapy stratified on the basis of risk-factors for children with medulloblastoma,survival ratio and quality of life may be improved.The long-term survival of such children has correlation with risk factors.

The cochlear dose and the age at radiotherapy predict severe hearing loss after passive scattering proton therapy and cisplatin in children with medulloblastoma

Risk factors for treatment-related sensorineural hearing loss and hearing aid use in medulloblastoma patients: an observational cohort study

Hearing Loss After Radiation and Chemotherapy for CNS and Head-and-Neck Tumors in Children

Dosimetric analysis of hearing loss after cranial radiation therapy in children: A single-institution study from the french national registry pediart

Predicting cisplatin ototoxicity in children: the influence of age and the cumulative dose

The cumulative incidence of cisplatin‐induced hearing loss in young children is higher and develops at an early stage during therapy compared with older children based on 2052 audiological assessments

Hearing Loss After Cisplatin-based Chemoradiotherapy for Locally Advanced Head and Neck Cancer: A Prospective Single-institution Study

Children with non-central nervous system tumors treated with platinum-based chemotherapy are at risk for hearing loss and cognitive impairments

Cisplatin Ototoxicity: Examination of the Impact of Dosing, Infusion Times, and Schedules In Pediatric Cancer Patients

Cisplatin ototoxicity in children: A practical grading system

Sensorineural Hearing Loss in Nasopharyngeal Carcinoma Survivors in the Modern Treatment Era - The Early and Late Effects of Radiation and Cisplatin

Patient-Reported Functional Impairment Due to Hearing Loss and Tinnitus After Cisplatin-Based Chemotherapy

MDB-27. OUTCOMES FOR CHILDREN TREATED FOR MEDULLOBLASTOMA USING A RADIATION-SPARING APPROACH: A REPORT FROM THE CHILDREN’S BRAIN TUMOR NETWORK

Audiological Outcomes of Weekly vs. Triweekly Cisplatin in Head and Neck Cancer with Cochlear-Sparing Intensity-Modulated Radiation Therapy

Clinical outcomes and late endocrine, neurocognitive, and visual profiles of proton radiation for pediatric low-grade gliomas

Clinical and effect analyses of comprehensive treatment for medulloblastoma: a report of 115 children

The association between skeletal muscle mass and sensorineural hearing loss upon cisplatin-based chemoradiotherapy in patients with head and neck squamous cell carcinoma

Clinical Predictors of Cisplatin Chemoradiation-Induced Ototoxicity in HPV-Positive Oropharyngeal Squamous Cell Carcinoma: A Case-Control Study

Predicting Hearing Loss in Testicular Cancer Patients after Cisplatin-Based Chemotherapy

Polygenic risk scores, radiation treatment exposures and subsequent cancer risk in childhood cancer survivors

Pooled Analysis of Meningioma Risk Following Treatment for Childhood Cancer